当前位置: 首页 >> 检索结果
5944. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
作者: Tom H Karlsen.;Nick Sheron.;Shira Zelber-Sagi.;Patrizia Carrieri.;Geoffrey Dusheiko.;Elisabetta Bugianesi.;Rachel Pryke.;Sharon J Hutchinson.;Bruno Sangro.;Natasha K Martin.;Michele Cecchini.;Mae Ashworth Dirac.;Annalisa Belloni.;Miquel Serra-Burriel.;Cyriel Y Ponsioen.;Brittney Sheena.;Alienor Lerouge.;Marion Devaux.;Nick Scott.;Margaret Hellard.;Henkjan J Verkade.;Ekkehard Sturm.;Giulio Marchesini.;Hannele Yki-Järvinen.;Chris D Byrne.;Giovanni Targher.;Aviad Tur-Sinai.;Damon Barrett.;Michael Ninburg.;Tatjana Reic.;Alison Taylor.;Tim Rhodes.;Carla Treloar.;Claus Petersen.;Christoph Schramm.;Robert Flisiak.;Marieta Y Simonova.;Albert Pares.;Philip Johnson.;Alessandro Cucchetti.;Isabel Graupera.;Christos Lionis.;Elisa Pose.;Núria Fabrellas.;Ann T Ma.;Juan M Mendive.;Vincenzo Mazzaferro.;Harry Rutter.;Helena Cortez-Pinto.;Deirdre Kelly.;Robyn Burton.;Jeffrey V Lazarus.;Pere Ginès.;Maria Buti.;Philip N Newsome.;Patrizia Burra.;Michael P Manns.
来源: Lancet. 2022年399卷10319期61-116页 5945. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
作者: Alasdair P S Munro.;Leila Janani.;Victoria Cornelius.;Parvinder K Aley.;Gavin Babbage.;David Baxter.;Marcin Bula.;Katrina Cathie.;Krishna Chatterjee.;Kate Dodd.;Yvanne Enever.;Karishma Gokani.;Anna L Goodman.;Christopher A Green.;Linda Harndahl.;John Haughney.;Alexander Hicks.;Agatha A van der Klaauw.;Jonathan Kwok.;Teresa Lambe.;Vincenzo Libri.;Martin J Llewelyn.;Alastair C McGregor.;Angela M Minassian.;Patrick Moore.;Mehmood Mughal.;Yama F Mujadidi.;Jennifer Murira.;Orod Osanlou.;Rostam Osanlou.;Daniel R Owens.;Mihaela Pacurar.;Adrian Palfreeman.;Daniel Pan.;Tommy Rampling.;Karen Regan.;Stephen Saich.;Jo Salkeld.;Dinesh Saralaya.;Sunil Sharma.;Ray Sheridan.;Ann Sturdy.;Emma C Thomson.;Shirley Todd.;Chris Twelves.;Robert C Read.;Sue Charlton.;Bassam Hallis.;Mary Ramsay.;Nick Andrews.;Jonathan S Nguyen-Van-Tam.;Matthew D Snape.;Xinxue Liu.;Saul N Faust.; .
来源: Lancet. 2021年398卷10318期2258-2276页
Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT).
|